Skip to main content

Steroide bei Sehnerverkrankungen?

Steroids for optic nerve diseases?

Der Ophthalmologe volume 104, pages 517–520 (2007)Cite this article

Zusammenfassung

Erkrankungen des Sehnervs sind in Deutschland die dritthäufigste Erblindungsursache. Häufige Sehnerverkrankungen sind u. a. die Neuritis nervi optici und die traumatische Optikusneuropathie. Diese Erkrankungen werden häufig mit Steroiden behandelt. Bei der Behandlung der traumatischen Optikusneuropathie muss entsprechend neuerer Erkenntnisse davon ausgegangen werden, dass Steroide nicht von Nutzen sind und in sehr hoher Dosis bezüglich allgemeiner Nebenwirkungen sogar als gefährlich einzustufen sind. Ebenso ist bei Neuritis nervi optici der Nutzen hoch dosierter Steroide aufgrund aktueller Ergebnisse fraglich.

Abstract

Diseases of the optic nerve are the third most common cause of blindness in Germany. Common optic nerve diseases include optic nerve neuritis and traumatic optic neuropathy. These diseases are often treated with steroids. In the case of traumatic optic neuropathy, recent results indicate that such treatment is not of value, and can even be dangerous due to the side effects if the doses are high. Based on current results, the value of high dose steroid treatment for optic nerve neuritis is also questionable.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Literatur

  1. Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49: 1404–1413

    PubMed  Google Scholar 

  2. Auphan N, DiDonato JA, Rosette C et al. (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286–290

    PubMed  Google Scholar 

  3. Beck RW, Cleary PA, Anderson MM Jr et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326: 581–588

    PubMed  Google Scholar 

  4. Beck RW, Gal RL, Bhatti MT et al. (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137: 77–83

    Article  PubMed  Google Scholar 

  5. Bracken MB, Shepard MJ, Collins WF et al. (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322: 1405–1411

    PubMed  Google Scholar 

  6. Bracken MB, Shepard MJ, Holford TR et al. (1997) Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277: 1597–1604

    Article  PubMed  Google Scholar 

  7. Buttgereit F, Wehling M, Burmester GR (1998) A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 41: 761–767

    PubMed  Google Scholar 

  8. Diem R, Hobom M, Maier K et al. (2003) Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 23: 6993–7000

    PubMed  Google Scholar 

  9. Elovaara I, Ukkonen M, Leppakynnas M et al. (2000) Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 57: 546–551

    PubMed  Google Scholar 

  10. Falkenstein E, Tillmann HC, Christ M et al. (2000) Multiple actions of steroid hormones–a focus on rapid, nongenomic effects. Pharmacol Rev 52: 513–556

    PubMed  Google Scholar 

  11. Frohman E, Costello F, Zivadinov R et al. (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol 5: 853–863

    PubMed  Google Scholar 

  12. Gelati M, Corsini E, De Rossi M et al. (2002) Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch Neurol 59: 774–780

    PubMed  Google Scholar 

  13. Gold R, Buttgereit F, Toyka KV (2001) Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117: 1–8

    PubMed  Google Scholar 

  14. Gould ES, Bird AC, Leaver PK, McDonald WI (1977) Treatmenf of optic neuritis by retrobulbar injection of triamcinolone. Br Med J 1: 1495–1497

    PubMed  Google Scholar 

  15. Hickman SJ, Kapoor R, Jones SJ et al. (2003) Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry 74: 1139–1141

    Article  PubMed  Google Scholar 

  16. Joyce DA, Steer JH, Abraham LJ (1997) Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-alpha secretion. Inflamm Res 46: 447–451

    PubMed  Google Scholar 

  17. Kapoor R, Miller DH, Jones SJ et al. (1998) Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 50: 230–237

    PubMed  Google Scholar 

  18. Kappos L, Antel J, Comi G et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124–1140

    Article  PubMed  Google Scholar 

  19. Levin LA, Beck RW, Joseph MP et al. (1999) The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology 106: 1268–1277

    Article  PubMed  Google Scholar 

  20. Mangelsdorf DJ, Thummel C, Beato M et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835–839

    Article  PubMed  Google Scholar 

  21. McDonald WI, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127

    Article  PubMed  Google Scholar 

  22. Ohlsson M, Mattsson P, Svensson M (2004) A temporal study of axonal degeneration and glial scar formation following a standardized crush injury of the optic nerve in the adult rat. Restor Neurol Neurosci 22: 1–10

    PubMed  Google Scholar 

  23. Ohlsson M, Westerlund U, Langmoen IA, Svensson M (2004) Methylprednisolone treatment does not influence axonal regeneration or degeneration following optic nerve injury in the adult rat. J Neuroophthalmol 24: 11–18

    PubMed  Google Scholar 

  24. Polman CH, Reingold SC, Edan G et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“. Ann Neurol 58: 840–846

    Article  PubMed  Google Scholar 

  25. Reagan LP, McEwen BS (1997) Controversies surrounding glucocorticoid-mediated cell death in the hippocampus. J Chem Neuroanat 13: 149–167

    PubMed  Google Scholar 

  26. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med 353: 1711–1723

    PubMed  Google Scholar 

  27. Roberts I, Yates D, Sandercock P et al. (2004) Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 364: 1321–1328

    Article  PubMed  Google Scholar 

  28. Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57: 925–935

    PubMed  Google Scholar 

  29. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283–286

    PubMed  Google Scholar 

  30. Schmidt J, Gold R, Schonrock L et al. (2000) T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123: 1431–1441

    PubMed  Google Scholar 

  31. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52: 1479–1484

    PubMed  Google Scholar 

  32. Sheng Y, Zhu Y, Wu L (2004) Effect of high dosage of methylprednisolone on rat retinal ganglion cell apoptosis after optic nerve crush. Yan Ke Xue Bao 20: 181–186

    PubMed  Google Scholar 

  33. Steel DH, Waldock A (1998) Measurement of the retinal nerve fibre layer with scanning laser polarimetry in patients with previous demyelinating optic neuritis. J Neurol Neurosurg Psychiatry 64: 505–509

    PubMed  Google Scholar 

  34. Steinsapir KD (2006) Treatment of traumatic optic neuropathy with high-dose corticosteroid. J Neuroophthalmol 26: 65–67

    PubMed  Google Scholar 

  35. Steinsapir KD, Goldberg RA, Sinha S, Hovda DA (2000) Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor Neurol Neurosci 17: 157–163

    PubMed  Google Scholar 

  36. Trapp BD, Peterson J, Ransohoff RM et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278–285

    PubMed  Google Scholar 

  37. Trautner C, Haastert B, Richter B et al. (2003) Incidence of blindness in southern Germany due to glaucoma and degenerative conditions. Invest Ophthalmol Vis Sci 44: 1031–1034

    Article  PubMed  Google Scholar 

  38. Trauzettel-Klosinski S, Diener HC, Dietz K, Zrenner E (1995) The effect of oral prednisolone on visual evoked potential latencies in acute optic neuritis monitored in a prospective, randomized, controlled study. Doc Ophthalmol 91: 165–179

    PubMed  Google Scholar 

  39. Trip SA, Schlottmann PG, Jones SJ et al. (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58: 383–391

    PubMed  Google Scholar 

  40. Trip SA, Schlottmann PG, Jones SJ et al. (2006) Quantification of optic nerve head topography in optic neuritis: a pilot study. Br J Ophthalmol 90: 1128–1131

    PubMed  Google Scholar 

  41. Vedula S, Brodney-Folse S, Gal R, Beck R (2007) Corticosteroids for treating optic neuritis. Cochrane database of systematic reviews. (Online): CD001430

  42. Wakakura M, Mashimo K, Oono S et al. (1999) Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 43: 133–138

    PubMed  Google Scholar 

  43. Watters JJ, Campbell JS, Cunningham MJ et al. (1997) Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138: 4030–4033

    PubMed  Google Scholar 

  44. Yip CC, Chng NW, Au Eong KG et al. (2002) Low-dose intravenous methylprednisolone or conservative treatment in the management of traumatic optic neuropathy. Eur J Ophthalmol 12: 309–314

    PubMed  Google Scholar 

  45. Yudt MR, Cidlowski JA (2002) The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol 16: 1719–1726

    PubMed  Google Scholar 

  46. Zipp F, Wendling U, Beyer M et al. (2000) Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells. J Neuroimmunol 110: 214–222

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Affiliations

  1. Universitäts-Augenklinik Freiburg, Killianstraße 5, 79106, Freiburg, Deutschland

    W.A. Lagrèze

Authors
  1. W.A. Lagrèze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W.A. Lagrèze.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lagrèze, W. Steroide bei Sehnerverkrankungen?. Ophthalmologe 104, 517–520 (2007). https://doi.org/10.1007/s00347-007-1525-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-007-1525-x

Schlüsselwörter

  • Neuritis nervi optici
  • Traumatische Optikusneuropathie
  • Steroide

Keywords

  • Optic nerve neuritis
  • Traumatic optic neuropathy (TON)
  • Steroids